Nektar Therapeutics (NKTR)

Market Cap	1.33B +713.3%
Revenue (ttm)	62.60M -32.8%
Net Income	-120.74M
EPS	-7.90
Shares Out	20.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,803,917
Open	59.00
Previous Close	56.00
Day's Range	58.95 - 67.94
52-Week Range	6.48 - 67.78
Beta	1.34
Analysts	Strong Buy
Price Target	122.33 (+87.48%)
Earnings Date	Mar 11, 2026

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $122.33, which is an increase of 87.48% from the latest price.

Price Target

$122.33

(87.48% upside)

Analyst Consensus: Strong Buy